NASDAQ:JSPR Jasper Therapeutics Q4 2025 Earnings Report $0.59 +0.02 (+3.28%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$0.57 -0.02 (-2.80%) As of 09/24/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Jasper Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.79Beat/MissBeat by +$0.47One Year Ago EPSN/AJasper Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJasper Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeBefore Market OpensConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETUpcoming EarningsJasper Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Jasper Therapeutics Earnings HeadlinesJasper Therapeutics (NASDAQ:JSPR) Cut to Sell at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 18, 2026 | americanbankingnews.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | Paradigm Press (Ad)Jasper Therapeutics Announces Key Regulatory and Clinical AppointmentsSeptember 15, 2026 | globenewswire.comJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | globenewswire.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deSee More Jasper Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email. Email Address About Jasper TherapeuticsJasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells. Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity. The company has evaluated briquilimab in mast cell-mediated diseases, including chronic spontaneous urticaria, and in conditioning regimens intended to prepare patients for hematopoietic stem cell transplantation or certain gene therapies. These programs remain subject to clinical testing and regulatory review. Founded in 2019 and headquartered in Redwood City, California, Jasper Therapeutics serves the global biopharmaceutical and clinical research markets through its development programs. The company’s activities are focused primarily on advancing briquilimab and related therapies rather than selling commercial products.View Jasper Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
